Intra-Arterial Chemotherapy in Liver Metastatic Bladder Cancer: Refractory to Standard Therapy: Two Case Reports

Laura Ginocchi1*, Alessio Auci2, Chiara Valsuani1, Simona Bursi1, Maurizio Lucchesi1, Paola Paccetti1, Gianmaria Fiorentini2, Stefano Guadagni4, Vittorio Gebbia3 and Andrea Mambriti1

1Medical Oncology Unit, North West Tuscany Company, New Apuane Hospital (NOA), Massa (MS), Italy
2Interventional Radiological Unit, North West Tuscany Company, New Apuane Hospital (NOA), Massa (MS), Italy
3Medical Oncology Unit, San Salvatore Hospital, Muraglia, Pesaro (PU), Italy
4Department of Applied Clinical Sciences and Biotechnology, University of L’Aquila, L’Aquila (AQ), Italy
5Medical Oncology Unit, La Maddalena Hospital, Palermo (PA), Italy

Abstract

Bladder cancer is the commonest malignancy of the urinary tract. Unfortunately most patients develop metastases during the course of their medical history. In this setting, chemotherapy treatment remains the only therapeutic option. Today, there is not standard therapy over the second line chemotherapy.

We reported our experience with intra-arterial chemotherapy in two patients with metastatic bladder cancer liver progression disease after standard chemotherapy. The schedule used consisted in epirubicin 35 mg/mq and cisplatin 42 mg/mq administered into hepatic artery proper by bolus injection through a catheter inserted in the femoral artery with the Seldinger method, with cycles repeated every 21 days. Intra-arterial chemotherapy provided a good liver disease control, allowing to treat disease progression with radiotherapy, without important adverse events. Interesting, intra-arterial chemotherapy was well tolerated despite age, previous treatment and related residual toxicities.

Keywords: Bladder; Cancer; Chemotherapy; Intra-arterial; Liver; Metastases

Introduction

Bladder cancer is the commonest malignancy of the urinary tract, with the incidence being four times higher in men than in women [1]. About 50% of patients who underwent radical cystectomy for invasive bladder cancer develops recovery of local or distant disease, while approximately 10-15% of patients present with metastatic disease at time of diagnosis [2], especially in liver, bone and lung. In metastatic setting, chemotherapy treatment remains the only therapeutic option. Although recent advances have improved outcomes in second line therapy, the vast majority of patients have disease recurrence or progression within few months, with a 5-years survival rate of less than 10%. Furthermore, treatment options in subsequent lines are limited, partly because patient clinical conditions are deteriorated and chemotherapy is often burdened by significant side effects. We reported our experience with intra-arterial chemotherapy in two patients with metastatic bladder cancer liver progression disease.

Materials and Methods

We described two case reports of metastatic pre-treated bladder cancer subjected to intra-arterial chemotherapy. The first patient was 80 years old; in his medical history myocardial infarction six years ago, with an actual ejection fraction of 45%. In December 2012 he underwent to radical cystectomy with lymphadenectomy and prostatectomy due to infiltrating urothelial carcinoma pT2N1G3, followed by 5 cycles of adjuvant chemotherapy with carboplatin plus gemcitabine in other oncological department. Following the appearance of worsening low back pain, in March 2015 he performed a bone scan and CT scan that showed the presence of right pelvis, liver and lymph nodes metastasis. Given the time elapsed since the term adjuvant therapy and the good general condition (ECOG PS 0), the patient has been subjected to 3 cycles of carboplatin first-line chemotherapy in association with gemcitabine, followed by concomitant gemcitabine-pelvis radiotherapy (33 Gy total dose). The treatment was discretely tolerated with just a grade 1 peripheral neurotoxicity. The next restaging CT scan evidenced a liver and bone progression disease, with lymph nodes disease stability. So, from July to September 2015, he underwent to a vinflunina second-line chemotherapy. After 3 cycles of chemotherapy, a total body CT showed bone and lymph nodes disease partial response but a liver progression disease. Therefore, vinflunina therapy was not well tolerated due to G4 neutropenia and severe asthenia. In October 2015, the patient went in our Oncological Department: considering general condition (ECOG PS 2), age, recent side effects and previous received therapies, as well as the only site of hepatic progression, we decided to subject the patient to cisplatin-epirubicin intra-arterial chemotherapy with the Seldinger method. Regional chemotherapy were administered through an angiographic catheter (Simmons 2; 5 Fr) introduced via the femoral artery into hepatic artery. The schedule used consisted in epirubicin 35 mg/mq and cisplatin 42 mg/mq diluted in 100 ml of normal saline and then infused over a period of 10 minutes, with cycles repeated every 21 days. After 3 cycles, restaging CT scan showed a right hepatic lobe metastasis reduction and a slight increase of those left. We decided to proceed the subsequent 3 cycles with a selective catheterization of
the right and left hepatic arteries, infusing respectively 40 and 60% of the drugs, in order to better perfuse the left lobe, where there has been a minor response. CT scan performed in February 2016, showed a liver stable disease but a bone progression. Loco regional treatment was well tolerated, with the exception of a grade 2 transient increases in transaminases and mild asthenia. Due to bone progression disease with pain and physically disabled, patient underwent to palliative sacral radiotherapy in March 2016, and continued intra-arterial treatment for additional 2 cycles, until May 2016. Unfortunately, restaging CT scan showed an important liver, bone and lung progression disease, furthermore the patient had a severe deterioration of the general conditions (ECOG PS 3), so we decided to continue just supportive care. The patient died in September 2nd, 2016.

The second patient is 64 years old without comorbidities. In March 2013 he had diagnosis of infiltrating urothelial carcinoma, cT4N2M1 (metastasis in abdominal lymph nodes and bone). From May to October 2013, he performed 6 cycles of first-line cisplatin-gemcitabine chemotherapy with good tolerance and stability disease. In March 2014, due to lymph nodes and bone progression disease, he was subjected to weekly paclitaxel second-line chemotherapy, followed by concomitant chemo-radiotherapy on abdominal lymph nodes and on first and second lumbar vertebrae, until October 2014. Treatment was discretely tolerated, except for the grade 2 peripheral neuropathy and moderate asthenia and anorexia appearance. Unfortunately, restaging CT scan performed in December 2014 showed the appearance of liver metastases, with stability of the remaining lesions. Considering general condition (ECOG PS 2), residual grade 2 peripheral neurotoxicity, persistent moderate asthenia and anorexia, previous received therapies and the only site of hepatic progression, we proposed to the patient a loco regional approach with cisplatin-epirubicin intra-arterial chemotherapy. So, from January to July 2015, he received 6 cycles of epirubicin 35 mg/mq and cisplatin 42 mg/mq chemotherapy, administered into hepatic artery proper by bolus injection through a catheter inserted in the femoral artery with the Seldinger method (each cycle was repeated every 21 days). Loco regional treatment was well tolerated without any side effect, patient general condition improved with resolving of anorexia and residual grade 1 asthenia and reduction of hepatic lesions. In August 2015, treatment was temporarily suspended due to enforcement of antalgic palliative pelvis radiotherapy and it was restarted for further 2 cycles, until October 2015. The next revaluation CT scan showed a lung progression disease, so the patient resumed weekly paclitaxel. Chemotherapy was finally stopped in February 2016, due to general condition progressive deterioration.

Results

Both patients received platinum combination first-line chemotherapy with a PFS of 3.23 months for the first elderly patient (carboplatin plus gemcitabine) and 10.13 months for the second younger patient (cisplatin plus gemcitabine). At the progression, also second-line chemotherapy awarded a PFS of 9.1 month in patient 2. Considering the subsequent progression disease just in the liver, second-line chemotherapy awarded a PFS of 9.1 month in patient 2.

Discussion

Bladder cancer is one of the most aggressive and a poor prognosis tumor. Cisplatin containing first-line chemotherapy can prolong median OS until 14 months, especially in patients with only lymph nodes disease and good PS [3-11]. Vinflunina second-line chemotherapy showed an advantage of just 2.6 months versus best supportive care (6.9 vs 4.3 months respectively), at expense of significant haematological and not toxicities [12,13]. Despite these survival data, some patient is candidates to a third-line regime. Obviously, a further course of treatment should take into account the previous received therapies, residual toxicities, patient general condition and any future side effects. Considering that, today, there is no consensus schedule in these patients and our experience with loco regional chemotherapy [14,15], we submitted two pre-treated patients with hepatic metastasis bladder cancer to intra-arterial chemotherapy. Both patient received a platinum combination first-line chemotherapy with a PFS of 3.23 months for the first elderly patient (carboplatin plus gemcitabine) and 10.13 months for the second younger patient (cisplatin plus gemcitabine). At the progression, also second-line chemotherapy had poor effect in patient 1 (PFS 2.5 month with vinflunina), while paclitaxel second-line chemotherapy awarded a PFS of 9.1 month in patient 2. Considering the subsequent progression disease just in the liver, residual toxicities and general condition, we proposed to both patients a loco regional approach with cisplatin-epirubicin intra-arterial chemotherapy (epirubicin 35 mg/mq plus cisplatin 42 mg/mq chemotherapy, administered into hepatic artery proper by bolus injection through a catheter inserted in the femoral artery with the Seldinger method. Each cycle was repeated every 21 days). Restaging CT scan showed a good liver disease controls in both cases, with a third-line therapy PFS of 8.97 and 12.1 month in the first and second patient, respectively. Very important, no grade 3-4 toxicities were reported, rather, patient ECOG PS improved during treatment. Globally, OS was 45.7 month for patient 1 and 38.7 for patient 2.

References


Journal of Anesthesia & Clinical Care
Journal of Addiction & Addictive Disorders
Advances in Microbiology Research
Advances in Industrial Biotechnology
Journal of Agronomy & Agricultural Science
Journal of AIDS Clinical Research & STDs
Journal of Alcoholism, Drug Abuse & Substance Dependence
Journal of Allergy Disorders & Therapy
Journal of Alzheimer’s & Neurodegenerative Diseases
Journal of Angiology & Vascular Surgery
Journal of Animal Research & Veterinary Science
Archives of Zoological Studies
Archives of Urology
Journal of Atmospheric & Earth-Sciences
Journal of Aquaculture & Fisheries
Journal of Biotech Research & Biochemistry
Journal of Brain & Neuroscience Research
Journal of Cancer Biology & Treatment
Journal of Cardiology: Study & Research
Journal of Cell Biology & Cell Metabolism
Journal of Clinical Dermatology & Therapy
Journal of Clinical Immunology & Immunotherapy
Journal of Clinical Studies & Medical Case Reports
Journal of Community Medicine & Public Health Care
Current Trends: Medical & Biological Engineering
Journal of Cytology & Tissue Biology
Journal of Dentistry: Oral Health & Cosmesis
Journal of Diabetes & Metabolic Disorders
Journal of Dairy Research & Technology
Journal of Emergency Medicine Trauma & Surgical Care
Journal of Environmental Science: Current Research
Journal of Food Science & Nutrition
Journal of Forensic, Legal & Investigative Sciences
Journal of Gastroenterology & Hepatology Research
Journal of Gerontology & Geriatric Medicine
Journal of Genetics & Genomic Sciences
Journal of Hematology, Blood Transfusion & Disorders
Journal of Human Endocrinology
Journal of Hospice & Palliative Medical Care
Journal of Internal Medicine & Primary Healthcare
Journal of Infectious & Non Infectious Diseases
Journal of Light & Laser: Current Trends
Journal of Modern Chemical Sciences
Journal of Medicine: Study & Research
Journal of Nanotechnology: Nanomedicine & Nanobiotechnology
Journal of Neonatology & Clinical Pediatrics
Journal of Nephrology & Renal Therapy
Journal of Non Invasive Vascular Investigation
Journal of Nuclear Medicine, Radiology & Radiation Therapy
Journal of Obesity & Weight Loss
Journal of Orthopedic Research & Physiotherapy
Journal of Otolaryngology, Head & Neck Surgery
Journal of Protein Research & Bioinformatics
Journal of Pathology Clinical & Medical Research
Journal of Pharmacology, Pharmaceutics & Pharmacovigilance
Journal of Physical Medicine, Rehabilitation & Disabilities
Journal of Plant Science: Current Research
Journal of Psychiatry, Depression & Anxiety
Journal of Pulmonary Medicine & Respiratory Research
Journal of Practical & Professional Nursing
Journal of Reproductive Medicine, Gynaecology & Obstetrics
Journal of Stem Cells Research, Development & Therapy
Journal of Surgery: Current Trends & Innovations
Journal of Toxicology: Current Research
Journal of Translational Science and Research
Trends in Anatomy & Physiology
Journal of Vaccines Research & Vaccination
Journal of Virology & Antivirals
Archives of Surgery and Surgical Education
Sports Medicine and Injury Care Journal
International Journal of Case Reports and Therapeutic Studies

Submit Your Manuscript: http://www.heraldopenaccess.us/Online-Submission.php